Truist Securities Starts Tourmaline Bio (TRML) at Buy, 'A revitalized approach to thyroid eye disease and beyond'
Tweet Send to a Friend
(Updated - November 16, 2023 4:03 PM EST)
Truist Securities analyst Robyn Karnauskas initiates coverage on Tourmaline Bio (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Truist Securities analyst Robyn Karnauskas initiates coverage on Tourmaline Bio (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
